Morgan Dempsey Capital Management’s AbbVie ABBV Stock Holding History

Morgan Dempsey Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.2K	Hold	100	–	–	0.01%	89
2026 Q1	$21.7K	Hold	100	–	–	0.01%	97
2025 Q4	$22.8K	Hold	100	–	–	0.01%	96
2025 Q3	$23.2K	Hold	100	–	–	0.01%	101
2025 Q2	$18.6K	Buy	+100	New	+$18.6K	0.01%	103
2016 Q3	–	Sell	-29	Closed	-$2K	–	155
2016 Q2	$2K	Buy	+29	New	+$1.77K	﹤0.01%	170

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Dempsey Capital Management's ABBV Position: Q2 2026 in Review

Morgan Dempsey Capital Management held its AbbVie (ABBV) position steady in Q2 2026 at 100 shares worth $25.2K. The position accounts for 0.01% of the portfolio, ranked #89.

Morgan Dempsey Capital Management first reported a position in ABBV in Q2 2016 and has held it in 6 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Morgan Dempsey Capital Management held 100 shares of AbbVie worth $25.2K as of Q2 2026.
Morgan Dempsey Capital Management left its AbbVie share count unchanged in Q2 2026.
AbbVie made up 0.01% of Morgan Dempsey Capital Management's portfolio in Q2 2026, its #89 holding.
Morgan Dempsey Capital Management first reported a position in AbbVie in Q2 2016 and has held it in 6 quarters since.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Morgan Dempsey Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.